Patients Previously Treated for Nonfunctioning Pituitary Macroadenomas Have Disturbed Sleep Characteristics, Circadian Movement Rhythm, and Subjective Sleep Quality

Biermasz, Nienke R.; Joustra, Sjoerd D; Donga, Esther; Pereira, Alberto M.; Duinen, Nicolette van; Dijk, Marie van; Klaauw, Agatha A. van der; Corssmit, Eleonora P M; Lammers, Gert Jan; Kralingen, Klaas W. van; Dijk, J. Gert van; Romijn, Johannes A.

doi:10.1210/jc.2010-2742

Cited by 53 publications

(55 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings are in accordance with previous results about QoL in patients with pituitary adenomas (1) as well as with results about the subjective sleep quality of individual patient groups, e.g. of acromegaly (10), NFPAs (14), or craniopharyngeomas (44). .746, P!0.001).…”

Section: Discussionsupporting

confidence: 92%

“…In addition, Van der Klaauw et al (13) concluded that patients cured from craniopharyngiomas or nonfunctioning macroadenomas suffered from increased daytime somnolence despite normal sleep patterns (onset, sleep timing, duration, and rise time) compared with healthy controls. Furthermore, Biermasz et al (14) observed reduced sleep efficiency, less rapid eye movement sleep, more N1 sleep, and more awakenings in the absence of excessive apnea or periodic limb movements in patients previously treated for nonfunctioning pituitary macroadenomas compared with age-, gender-, and BMImatched controls. Actigraphy revealed a longer sleep duration and profound disturbances in diurnal movement patterns, with more awakenings at night and less activity during the day.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Reduced sleep quality and depression associate with decreased quality of life in patients with pituitary adenomas

Leistner

Klotsche

Dimopoulou

et al. 2015

European Journal of Endocrinology

View full text Add to dashboard Cite

Objectives: Several studies reported decreased quality of life (QoL) and sleep as well as increased rates of depression for patients with pituitary adenomas. Our aim was to explore to what extent differences in depression and sleep quality contribute to differences in QoL between patients with pituitary adenomas and controls. Design: A cross-sectional case-control study. Setting: Endocrine Outpatient Unit of the Max Planck Institute of Psychiatry, Munich, Department of Internal Medicine, Ludwig-Maximilians-University, Munich, and the Institute of Clinical Psychology and Psychotherapy, Technical University, Dresden. Participants: Patients with pituitary adenomas (nZ247) and controls (from the DETECT cohort, a large epidemiological study in primary care patients) matched individually by age and gender (nZ757). Measurements: Sleep quality was assessed with the Pittsburgh Sleep Quality Index (PSQI) and QoL was measured by the generic EQ-5D and calculated by the time trade-off-and VAS-method. Depression was categorized as 'no depression', 'subclinical depression', and 'clinical depression' according to the Beck Depressions Inventory for patients and the Depression Screening Questionnaire for control subjects. Statistical analyses: General linear and generalized, logistic mixed models as well as proportional odds mixed models were calculated for analyzing differences in baseline characteristics and in different subgroups. Results: Patients with pituitary adenomas showed decreased QoL (VAS index: 0.73G0.19) and sleep (PSQI score: 6.75G4.17) as well as increased rates of depression (subclinical or clinical depression: 41.4%) compared with their matched control subjects (VAS index: 0.79G0.18, PSQI score: 5.66G4.31, subclinical or clinical depression: 25.9%). We have shown that a substantial proportion of the reduced QoL (48% respectively 65%) was due to the incidence of depression and reduced sleep quality. Conclusions: These findings emphasize the importance of diagnosing depressive symptoms and sleep disturbances in patients with pituitary disease, with the ultimate goal to improve QoL in patients with pituitary adenomas.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Reduced sleep quality and depression associate with decreased quality of life in patients with pituitary adenomas

Leistner

Klotsche

Dimopoulou

et al. 2015

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Although most reports on QoL using generic questionnaires in NFPA describe a low QoL after treatment (7,11,41,75,76), there are also descriptions of normalization of QoL, after successful treatment, attaining scores comparable to those seen in a healthy population (77,78). As already mentioned, compared to that of other pituitary adenoma patients, QoL of NFPA patients was similar to that of patients treated for prolactinoma, and better than that of patients diagnosed with CD and acromegaly (11,39,79,80).…”

Section: Non-functioning Pituitary Adenomasmentioning

confidence: 82%

“…Abnormal scores in energy, physical ability and anxiety have also been R23 Review S M Webb and others Quality of life in pituitary disease www.eje-online.org described in patients with NFPA who experience a tumour recurrence (77,81). A bad quality of sleep (reduced sleep efficiency, less rapid eye movement sleep and increased daytime somnolence) also determine poor QoL in these patients, and is often associated with fatigue, low motivation, more awakening at night and less activity during the day (11,75).…”

Section: Non-functioning Pituitary Adenomasmentioning

confidence: 99%

MANAGEMENT OF ENDOCRINE DISEASE: Quality of life tools for the management of pituitary disease

Webb

Crespo

Santos

et al. 2017

European Journal of Endocrinology

View full text Add to dashboard Cite

Background: In the last few years, quality of life (QoL) has become an outcome measure in patients with pituitary diseases. Objective: To describe the available data on QoL impairment evaluated with questionnaires in patients with pituitary diseases. Design: Critical review of the pertinent literature and pragmatic discussion of available information. Methods: Selection of relevant literature from PubMed and WOK, especially from the last 5 years and comprehensive analysis. Results: QoL is impaired in all pituitary diseases, mostly in acromegaly and Cushing's disease (similar to other causes of Cushing's syndrome), but also in non-functioning pituitary adenomas and prolactinomas, especially in the active phase of the disease. Nevertheless, even after endocrine 'cure', scores tend to be below normative values, indicative of residual morbidity after hormonal control. The presence of hypopituitarism worsens subjective QoL perception, which can improve after optimal substitution therapy, including recombinant human growth hormone, when indicated. Conclusions: To improve the long-term outcome of pituitary patients, helping them to attain the best possible health, it appears desirable to include subjective aspects captured when evaluating QoL, so that the affected dimensions are identified and if relevant treated. Additionally, being aware that treatment outcome may not always mean complete normalisation of physical and mental issues related to QoL can be a first step to adaptation and conforming to this new status.

show abstract

“…82 Disturbed sleep was associated with fatigue during the day and poor QoL. 82 Reduced energy, fatigue (mental and physical), physical problems, lower activity and motivation were previously reported in another study on operated NFA patients. 65 Thus, regulating patient's sleep-wake cycle is recommendable in order to ameliorate QoL.…”

Section: Non-functioning Pituitary Adenomasmentioning

confidence: 75%

Improving Quality of Life in Patients with Pituitary Tumours

Crespo¹,

Santos²,

Resmini³

et al. 2014

US Endocrinology

View full text Add to dashboard Cite

Evaluation of health-related quality of life (QoL) in people with pituitary tumours has received much attention over the last 10-15 years. Most of them show impaired QoL, but little is known about how to prevent impairment or how to improve QoL. Our aim is to review what is known about QoL in pituitary tumours patients and to highlight the areas worth improving, for the patient's well being. The article has four sections: acromegaly, Cushing's syndrome, prolactinomas and non-functioning adenomas. Control of comorbidities is usually an important factor to prevent QoL impairment; however, each disease has specific characteristics that should be properly addressed in order to obtain full patient recovery after successful therapy.

show abstract

Patients Previously Treated for Nonfunctioning Pituitary Macroadenomas Have Disturbed Sleep Characteristics, Circadian Movement Rhythm, and Subjective Sleep Quality

Cited by 53 publications

References 35 publications

Reduced sleep quality and depression associate with decreased quality of life in patients with pituitary adenomas

Reduced sleep quality and depression associate with decreased quality of life in patients with pituitary adenomas

MANAGEMENT OF ENDOCRINE DISEASE: Quality of life tools for the management of pituitary disease

Improving Quality of Life in Patients with Pituitary Tumours

Contact Info

Product

Resources

About